Pulmonx Corporation is a commercial-stage medical technology company that provides minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease. The company's solution consists of the Zephyr Endobronchial Valve, an implantable device used to occlude airways in hyperinflated lung lobes, the Chartis Pulmonary Assessment System, which uses balloon catheters and a console to assess collateral ventilation, and the LungTraX Platform, a cloud-based quantitative CT analysis service for patient selection. Pulmonx also manufactures the AeriSeal System, a synthetic polymer foam designed to close collateral air channels, which is currently undergoing clinical trials. The company sells its products in the United States through a direct sales organization and in international markets, including Europe, Asia Pacific, and Latin America, using both direct and distributor-based models. Pulmonx received pre-market approval from the U.S. Food and Drug Administration in 2018, and its products are included in global treatment guidelines for COPD.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage pulmonx.com
Sector Healthcare IR page investors.pulmonx.com
Tags
interventional pulmonology, endobronchial valves, chronic obstructive pulmonary disease, emphysema, lung volume reduction, pulmonary assessment, medical imaging analysis, minimally invasive surgery, Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, AeriSeal System, StratX Lung Analysis Reports
Press page —

Metrics

Valuation  
Market cap $ 83.182M
Market cap (USD) $ 83.182M
P/E -1.89
PEG —
P/BV 2.43
P/S 0.94
P/OCF -3.25
P/FCF -3.25
Dividend yield —
Turnover / mcap —
Returns  
ROE -77.2%
ROI -59.2%
ROIC -44.1%
Profit margin -59.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 110.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 1
Quality score -23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 90.497M 83.789M 68.675M 53.662M 48.416M 32.733M 32.595M
Net profit -54.003M -56.394M -60.843M -58.923M -48.661M -32.231M -20.703M
Free cash flow -32.828M -32.984M -38.417M -46.401M -45.059M -31.544M -21.52M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 2.21 6.79 12.75 8.43 32.07 69.02 —
Price performance 12m -0.67 -0.47 0.51 -0.74 -0.54 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 5.51M 4.23M 6.56M 8.68M 12.1M 13.1M 12.1M
↳ YoY growth -23.3% +55.2% +32.2% +39.5% +8.4% -8.0%
↳ 5y CAGR +18.9% +23.3%
Borrowings, current (USD) — — — 0.00 91,000 90,000 2.16M 3.18M 106,000
Borrowings, non-current (USD) — — — — 17.3M 17.2M 35.1M 34M 37M
Lease liabilities (USD) — — 6.85M 9.86M 9.05M 7.08M 4.18M 19.3M 19.3M
Cash and deposits (USD) 10.1M 4.12M 14.8M 232M 148M 102M 83.5M 70.9M 69.8M
Intangible assets (USD) — — 524,000 400,000 277,000 154,000 31,000 0.00 —
Right-of-use assets (USD) — — 6.56M 8.98M 8.08M 5.81M 3.41M 18.5M 18M
Net debt (borrowings + leases - cash) (USD) — — — -222M -122M -77.3M -42.1M -14.4M -13.4M
Cash flow detail
Operating cash flow (USD) — -18.4M -20.8M -30.6M -41.4M -45.1M -37.6M -31.5M -32.4M
Purchases of property, plant and equipment (USD) — -316,000 -720,000 -911,000 -3.67M -1.32M -807,000 -1.45M -452,000
Change in receivables (cash effect) (USD) — -262,000 -2.52M 1.46M -2.43M -2.19M -3.1M -1.31M 1.08M
Change in inventories (cash effect) (USD) — -1.25M -2.61M -5.05M -6.46M -3.64M 918,000 -229,000 -765,000
Change in payables (cash effect) (USD) — -648,000 524,000 592,000 87,000 247,000 -345,000 2.28M 270,000
Share buybacks (cash effect) (USD) — 0.00 -12,000 -21,000 -26,000 -27,000 0.00 — —
Interest paid (cash effect) (USD) — -1.36M -1.4M -3.06M -722,000 -847,000 -2.98M -3.48M -3.11M
Income taxes paid (cash effect) (USD) — -226,000 -196,000 -259,000 -322,000 -398,000 -471,000 -556,000 -468,000
Share-based compensation (USD) — 366,000 364,000 3.2M 10.5M 16.4M 22.1M 23M 21.2M
Operating cash flow before change in receivables (USD) — -18.1M -18.3M -32.1M -39M -42.9M -34.5M -30.2M -33.5M
Free cash flow (OCF - PPE - intangibles) (USD) — -18.7M -21.5M -31.5M -45.1M -46.4M -38.4M -33M -32.8M
Income detail
Research and development expense (USD) — 6.99M 6.05M 7.46M 13.1M 15.4M 18.1M 17.6M 19.5M
↳ 5y CAGR +20.9% +23.8% +21.2%
Total comprehensive income (USD) — -18.4M -20.7M -31.9M -48.6M -59.1M -59.8M -56.9M -53.8M
Comprehensive income to owners (USD) — -18.4M -20.7M -31.9M -48.6M -59.1M -59.8M -56.9M -53.8M
Provision for credit losses (USD) — -15,000 -4,000 -7,000 4,000 54,000 -59,000 40,000 0.00
Credit cost ratio (credit losses / average receivables) (%) — — — 0.1% 0.1% 0.7% 0.6% 0.3% 0.0%
Reported Mar 15, 2021 Mar 15, 2021 Mar 15, 2021 May 12, 2021 May 9, 2022 May 8, 2023 Feb 27, 2024 Feb 25, 2025 Mar 10, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Oct 28, 2026

PDF Version

REDWOOD CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Format: Fireside chat and 1x1 meetings Date: Wednesday, November 11 Fireside Chat Time: 9:30 AM – 9:55 AM ET

Stifel 2026 Healthcare Conference Format: Fireside chat and 1x1 meetings Date: Wednesday, November 11 Fireside Chat Time: 10:40 AM – 11:10 AM ET

Live and archived webcasts of the fireside chats will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX® Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, AeriSeal®, Chartis®, LungTraX®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Pulmonx Reports Third Quarter 2026 Financial Results Bull 3 Bear 0 Results

Oct 27, 2026

PDF Version

REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2026 ended September 30, 2026.

Recent Highlights

  • Achieved worldwide revenue of $22.8 million in the third quarter of 2026, a 6% increase over the same period last year on both a GAAP and constant currency basis

  • Delivered $14.9 million in U.S. revenue in the third quarter of 2026, representing a 7% year-over-year increase

  • Delivered $7.9 million in international revenue in the third quarter of 2026, representing a 5% year-over-year increase and an increase of 6% on a constant currency basis; excluding China, year-over-year international revenue increased 9% on both a GAAP and constant currency basis

  • Realized gross margin of 76% in the third quarter of 2026

  • Demonstrated continued operating leverage from cost realignment efforts, reducing net loss by 40% and Adjusted EBITDA loss by 57% in the third quarter of 2026 as compared to the same period last year

“We are very pleased to have returned to year-over-year revenue growth in the third quarter. We continue to execute on our commercial strategy, advance our clinical initiatives, and deliver the operating leverage we expected,” said Glen French, President and Chief Executive Officer of Pulmonx. “With a fully staffed U.S. sales leadership team, a more focused global commercial team, and a realigned cost structure, we are confident in our ability to build on this momentum and deliver growth while advancing our longer-term strategic priorities.”

Third Quarter 2026 Financial Results Total worldwide revenue in the third quarter of 2026 was $22.8 million, a 6% increase from $21.5 million in the third quarter of 2025 on both a GAAP and constant currency basis. U.S. revenue was $14.9 million, a 7% increase from the third quarter of 2025. International revenue was $7.9 million, a 5% increase compared to the third quarter of 2025, and a 6% increase on a constant currency basis. International revenue growth was tempered by an absence of sales to the Company’s distributor in China as we restart commercial activity in the region following the renewal of our Chinese registration certificate. Excluding China, international revenue grew 9% year-over-year on a GAAP and constant currency basis.

Gross profit in the third quarter of 2026 was $17.4 million, compared to $16.1 million for the third quarter of 2025. Gross margin for the third quarter of 2026 was 76%, compared to 75% for the same period in 2025.

Operating expenses in the third quarter of 2026 were $24.9 million, compared to $30.4 million for the third quarter of 2025, representing a decrease of 18%.

Net loss in the third quarter of 2026 was $8.4 million, or $0.19 per share, compared to a net loss of $14.0 million, or $0.34 per share, for the same period in 2025.

Adjusted EBITDA loss in the third quarter of 2026 was $3.5 million, a reduction of 57% as compared to adjusted EBITDA loss of $8.2 million for the same period in 2025.

Cash and cash equivalents totaled $52.7 million as of September 30, 2026.

2026 Financial Outlook Pulmonx continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million.

The Company now expects gross margin for the full year 2026 to be approximately 77%.

Pulmonx now expects total operating expenses for the full year 2026 to fall within the range of $108 million to $109 million, inclusive of approximately $14 million of non-cash stock-based compensation.

The Company now expects cash, cash equivalents, and marketable securities to decrease by approximately $22 million for the full year 2026 assuming no additional drawdowns under the Company’s credit facility.

Webcast and Conference Call Details Pulmonx will host a conference call today, October 27, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter financial results. A live webcast of the conference call will be available on the Investor Relations section of the Company’s website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call.

Use of Non-GAAP Financial Measures To supplement Pulmonx’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx’s business.

Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management’s financial and operational decision-making, including evaluation of Pulmonx’s historical operating results.

The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations, such as impairment charges. Management believes that, in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses Adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance.

Reconciliation of these non-GAAP financial measures to the most comparable GAAP measures is set forth in the tables below.

The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the Company’s reported results of operations, management strongly encourages investors to review, when they become available, the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company’s definition of non-GAAP measures may differ from similarly titled measures used by others.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our ability to drive improvements in revenue growth, execute on our commercial strategy, advance our strategic priorities, and deliver operating leverage, our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, balances of cash, cash equivalents, and marketable securities, profitability, guidance for full year 2026, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including the Quarterly Report on Form 10-Q filed with the SEC on August 4, 2026, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.

About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX® Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, AeriSeal®, Chartis®, LungTraX®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Investor Contact Brian Johnston or Webb Campbell Gilmartin Group [email protected]

| Pulmonx Corporation Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |

| | 2026 | | 2025 | | 2026 | | 2025 | |

| Revenue | $ | 22,835 | | | $ | 21,502 | | | $ | 66,177 | | | $ | 67,899 | | |

| Cost of goods sold | | 5,436 | | | | 5,450 | | | | 14,992 | | | | 18,301 | | |

| Gross profit | | 17,399 | | | | 16,052 | | | | 51,185 | | | | 49,598 | | |

| Operating expenses | | | | | | | | | | | | | | | | |

| Research and development | | 4,864 | | | | 4,846 | | | | 14,797 | | | | 14,908 | | |

| Selling, general and administrative | | 20,025 | | | | 25,599 | | | | 65,891 | | | | 78,450 | | |

| Total operating expenses | | 24,889 | | | | 30,445 | | | | 80,688 | | | | 93,358 | | |

| Loss from operations | | (7,490 | ) | | | (14,393 | ) | | | (29,503 | ) | | | (43,760 | ) | |

| Interest income | | 345 | | | | 611 | | | | 1,024 | | | | 2,198 | | |

| Interest expense | | (1,234 | ) | | | (805 | ) | | | (3,428 | ) | | | (2,385 | ) | |

| Other (expense) income, net | | 136 | | | | 758 | | | | 212 | | | | 809 | | |

| Net loss before tax | | (8,243 | ) | | | (13,829 | ) | | | (31,695 | ) | | | (43,138 | ) | |

| Income tax expense | | 151 | | | | 128 | | | | 433 | | | | 440 | | |

| Net loss | $ | (8,394 | ) | | $ | (13,957 | ) | | $ | (32,128 | ) | | $ | (43,578 | ) | |

| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.19 | ) | | $ | (0.34 | ) | | $ | (0.76 | ) | | $ | (1.08 | ) | |

| | | | | | | | | | | | | | | | | |

| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | | 43,176,913 | | | | 40,936,896 | | | | 42,519,134 | | | | 40,444,001 | | |

| |

| Pulmonx Corporation Condensed Consolidated Balance Sheets (in thousands) (Unaudited) |

| |

| | September 30, 2026 | | December 31, 2025 | |

| Assets | | | | | | | | |

| Current assets | | | | | | | | |

| Cash and cash equivalents | $ | 52,690 | | | $ | 69,751 | | |

| Restricted cash | | 257 | | | | 258 | | |

| Accounts receivable, net | | 12,014 | | | | 12,072 | | |

| Inventory | | 15,436 | | | | 15,845 | | |

| Prepaid expenses and other current assets | | 3,664 | | | | 3,758 | | |

| Total current assets | | 84,061 | | | | 101,684 | | |

| Long-term inventory | | 3,793 | | | | 3,604 | | |

| Property and equipment, net | | 1,761 | | | | 2,220 | | |

| Goodwill | | 2,333 | | | | 2,333 | | |

| Right of use assets | | 17,039 | | | | 18,028 | | |

| Other long-term assets | | 1,225 | | | | 1,422 | | |

| Total assets | $ | 110,212 | | | $ | 129,291 | | |

| | | | | | | | | |

| Liabilities and Stockholders' Equity | | | | | | | | |

| Current liabilities | | | | | | | | |

| Accounts payable | $ | 4,512 | | | $ | 3,905 | | |

| Accrued liabilities | | 14,555 | | | | 14,556 | | |

| Income taxes payable | | 171 | | | | 263 | | |

| Deferred revenue | | 12 | | | | 18 | | |

| Short-term debt | | 100 | | | | 106 | | |

| Current lease liabilities | | 1,389 | | | | 1,210 | | |

| Total current liabilities | | 20,739 | | | | 20,058 | | |

| Deferred tax liability | | 71 | | | | 69 | | |

| Long-term lease liabilities | | 17,145 | | | | 18,059 | | |

| Long-term debt | | 37,712 | | | | 36,989 | | |

| Common stock warrant liability | | 345 | | | | — | | |

| Total liabilities | | 76,012 | | | | 75,175 | | |

| Stockholders' equity | | | | | | | | |

| Common stock | | 44 | | | | 42 | | |

| Additional paid-in capital | | 586,127 | | | | 573,272 | | |

| Accumulated other comprehensive income | | 1,715 | | | | 2,360 | | |

| Accumulated deficit | | (553,686 | ) | | | (521,558 | ) | |

| Total stockholders' equity | | 34,200 | | | | 54,116 | | |

| | | | | | | | | |

| Total liabilities and stockholders' equity | $ | 110,212 | | | $ | 129,291 | | |

| |

| Pulmonx Corporation Reconciliation of Reported Revenue % Change to Constant Currency Revenue % Change (in thousands, except percentages) (Unaudited) |

| |

| | Three Months Ended September 30, | | | | | | | |

| | 2026 | | 2025 | | % Change | | FX Impact % | | Constant Currency % Change | |

| United States | $ | 14,911 | | $ | 13,967 | | | 6.8 | % | | — | % | | 6.8 | % | |

| International | | 7,924 | | | 7,535 | | | 5.2 | % | | (0.7 | )% | | 5.9 | % | |

| Total | $ | 22,835 | | $ | 21,502 | | | 6.2 | % | | (0.3 | )% | | 6.5 | % | |

| | | | | | | | | | | | | | | | | |

| | Three Months Ended September 30, | | | | | | | | | | |

| | 2026 | | 2025 | | % Change | | FX Impact % | | Constant Currency % Change | |

| International | $ | 7,924 | | $ | 7,535 | | | 5.2 | % | | (0.7 | )% | | 5.9 | % | |

| less China | | — | | | (234 | ) | | (100.0 | )% | | — | % | | (100.0 | )% | |

| International excluding China | $ | 7,924 | | $ | 7,301 | | | 8.5 | % | | (0.8 | )% | | 9.3 | % | |

| | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | |

| | Nine Months Ended September 30, | | | | | | | | | | |

| | 2026 | | 2025 | | % Change | | FX Impact % | | Constant Currency % Change | |

| United States | $ | 42,342 | | $ | 42,919 | | | (1.3 | )% | | — | % | | (1.3 | )% | |

| International | | 23,835 | | | 24,980 | | | (4.6 | )% | | 4.0 | % | | (8.6 | )% | |

| Total | $ | 66,177 | | $ | 67,899 | | | (2.5 | )% | | 1.5 | % | | (4.0 | )% | |

| | | | | | | | | | | | | | | | | |

| | | | | | | | | | | | | | | | | |

| | Nine Months Ended September 30, | | | | | | | | | | |

| | 2026 | | 2025 | | % Change | | FX Impact % | | Constant Currency % Change | |

| International | $ | 23,835 | | $ | 24,980 | | | (4.6 | )% | | 4.0 | % | | (8.6 | )% | |

| less China | | — | | | (4,014 | ) | | (100.0 | )% | | — | % | | (100.0 | )% | |

| International excluding China | $ | 23,835 | | $ | 20,966 | | | 13.7 | % | | 4.8 | % | | 8.9 | % | |

| |

| Pulmonx Corporation Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA (in thousands) (Unaudited) |

| |

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |

| | 2026 | | 2025 | | 2026 | | 2025 | |

| GAAP Net loss | $ | (8,394 | ) | | $ | (13,957 | ) | | $ | (32,128 | ) | | $ | (43,578 | ) | |

| Depreciation and amortization | | 215 | | | | 246 | | | | 657 | | | | 823 | | |

| Stock-based compensation | | 3,611 | | | | 5,166 | | | | 11,445 | | | | 16,992 | | |

| Interest (income)/expense, net | | 889 | | | | 194 | | | | 2,404 | | | | 187 | | |

| Provision for income taxes | | 151 | | | | 128 | | | | 433 | | | | 440 | | |

| Adjusted EBITDA | $ | (3,528 | ) | | $ | (8,223 | ) | | $ | (17,189 | ) | | $ | (25,136 | ) | |

Print Page

Print Page

Email Alerts

Email Alerts

Contact IR

Oct 13, 2026

PDF Version

REDWOOD CITY, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2026 after the close of trading on Tuesday, October 27, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

Prompts

Pulmonx Corporation (ticker LUNG), listed in United States.

ETFs Holding Pulmonx Corporation

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 14,209 $ 39.785K Nov 16, 2026